Isgaard Jörgen, Barlind Anna, Johansson Inger
Laboratory of Experimental Endocrinology, Department of Internal Medicine, Sahlgrenska Academy, Göteborg, Sweden.
Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):133-7. doi: 10.2174/187152908784533676.
Apart from promoting GH secretion and to regulate appetite and metabolism, it has become increasingly clear that GH secretagogues (GHS) and ghrelin exert a number of effects on the cardiovascular system. The main cardiovascular actions of GHS are possible inotropic effects, vasodilation, reported cardioprotective effects against ischemia, and in vitro effects on cardiomyocytes involving cell proliferation and anti-apoptotic actions. An interesting and intriguing feature of the cardiovascular effects of GHS is that they may be exerted directly on the heart and vasculature rather than being mediated by growth hormone. Evidence to suggest this is the finding of GHS binding sites on cardiomyocytes and the fact that some of the effects of GHS can be expressed also in the absence of GH. Taken together, these results offer an interesting perspective on the future where further studies aiming at evaluating a role of GHS and ghrelin in the treatment of cardiovascular disease are warranted.
除了促进生长激素（GH）分泌以及调节食欲和新陈代谢外，生长激素促分泌素（GHS）和胃饥饿素对心血管系统产生多种作用这一点已越来越清晰。GHS的主要心血管作用可能包括正性肌力作用、血管舒张、对缺血的心脏保护作用以及在体外对心肌细胞的作用，涉及细胞增殖和抗凋亡作用。GHS心血管效应的一个有趣且引人入胜的特点是，它们可能直接作用于心脏和血管系统，而非通过生长激素介导。表明这一点的证据是在心肌细胞上发现了GHS结合位点，以及GHS的一些作用在没有GH的情况下也能表现出来这一事实。综上所述，这些结果为未来提供了一个有趣的视角，即有必要进一步开展研究以评估GHS和胃饥饿素在心血管疾病治疗中的作用。
